|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 27/04 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/25/12 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 168.32Cr 5.22Cr 4.52Cr 4.24Cr 3.86Cr 7.27Cr 497.91Cr 7.39Cr 50Cr 19Cr 249.22Cr 20Cr 19Cr 831.44Cr | P/E 2024 |
-9.63x | P/E 2025 | -5.68x |
|---|---|---|---|---|---|
| Enterprise Value | 197.21Cr 6.12Cr 5.3Cr 4.96Cr 4.53Cr 8.52Cr 583.37Cr 8.66Cr 58Cr 23Cr 291.99Cr 23Cr 22Cr 974.14Cr | EV / Sales 2024 |
3.58x | EV / Sales 2025 | 3.83x |
| Free-Float |
27.79% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.79% |
| 3 years | 10 |  | 38.5 |
| 5 years | 10 | | 199.22 |
| 10 years | 8.34 | | 288.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jung Kuang Yang
CEO | Chief Executive Officer | - | - |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 11/04/2016 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 01/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Yun Fan
BRD | Director/Board Member | - | 30/06/2020 |
Yan Ning Kuo
BRD | Director/Board Member | - | 30/06/2020 |
Yao Hui Wei
BRD | Director/Board Member | - | 30/06/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -57.88% | 5.22Cr | |
| -0.75% | +9.65% | +92.58% | +131.57% | 1,09800Cr | |
| -1.24% | +1.58% | +48.98% | +48.96% | 63TCr | |
| +0.01% | +1.72% | +24.85% | +62.96% | 44TCr | |
| -1.13% | +3.13% | +49.78% | +39.13% | 37TCr | |
| -0.74% | +1.01% | +31.08% | +38.64% | 30TCr | |
| -1.22% | +0.89% | +7.32% | +7.38% | 25TCr | |
| -0.87% | +6.03% | +45.06% | +57.53% | 23TCr | |
| +0.34% | -0.13% | -4.77% | -50.50% | 21TCr | |
| +1.60% | -0.12% | +12.14% | +68.86% | 16TCr | |
| Average | -0.17% | +1,491.93% | +30.70% | +34.67% | 36.84TCr | |
| Weighted average by Cap. | -0.61% | +1,331.48% | +49.95% | +66.36% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 54Cr 1.67Cr 1.45Cr 1.36Cr 1.24Cr 2.33Cr 159.39Cr 2.37Cr 16Cr 6.23Cr 80Cr 6.27Cr 6.14Cr 266.16Cr | 51Cr 1.6Cr 1.38Cr 1.29Cr 1.18Cr 2.22Cr 152.18Cr 2.26Cr 15Cr 5.95Cr 76Cr 5.99Cr 5.86Cr 254.11Cr |
| Net income | -17Cr -54.13L -46.9L -43.91L -40.07L -75.4L -52Cr -76.66L -5.15Cr -2.02Cr -26Cr -2.03Cr -1.99Cr -86Cr | -30Cr -91.89L -79.63L -74.55L -68.02L -1.28Cr -88Cr -1.3Cr -8.74Cr -3.42Cr -44Cr -3.45Cr -3.38Cr -146.35Cr |
| Net Debt | 25Cr 76.4L 66.21L 61.99L 56.56L 1.06Cr 73Cr 1.08Cr 7.27Cr 2.85Cr 36Cr 2.87Cr 2.81Cr 121.69Cr | 29Cr 89.6L 77.65L 72.69L 66.32L 1.25Cr 85Cr 1.27Cr 8.52Cr 3.34Cr 43Cr 3.36Cr 3.29Cr 142.7Cr |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 6562 Stock
Select your edition
All financial news and data tailored to specific country editions
